FibrobiologicsFBLG
13F holders, Q2 2026 (June 30)16holders −1
3new positions
4sold out
$0.95avg. 13F price*
At the end of Q2 2026, 16 institutions reported holding Fibrobiologics Inc. (FBLG) in their 13F filings, down 1 from Q1 2026. 3 opened new positions and 4 sold out. The largest holders were Cascade Financial Partners, LLC ($103K), Fund Evaluation Group, LLC ($49K) and Geode Capital Management, LLC ($29K).
- Company
- Fibrobiologics Inc.
- CUSIP
- 31573L204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $30K |
| Exits | 4 | $23K |
All 13F filers, Q1 2026 → Q2 2026: 132,600 shares bought and 68,343 shares sold, net +64,257 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Cascade Financial Partners, LLC | 0.01% | Add +562.5% | 108,828 | $103K |
| Fund Evaluation Group, LLC | 0.00% | No change | 51,794 | $49K |
| Geode Capital Management, LLC | 0.00% | Add +2.3% | 30,299 | $29K |
| Vanguard Capital Management LLC | 0.00% | Reduce -59.0% | 27,769 | $26K |
| Qube Research & Technologies Ltd | 0.00% | New | 24,313 | $23K |
| BlackRock, Inc. | 0.00% | Reduce -26.0% | 18,238 | $17K |
| Barclays PLC | 0.00% | New | 7,243 | $7K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 6,380 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +927.8% | 4,728 | $4K |
| Osaic Holdings, Inc. | 0.00% | Add +1461.0% | 2,404 | $2K |
| UBS Group AG | 0.00% | Reduce -81.2% | 1,073 | $1K |
| Royal Bank of Canada | 0.00% | Add +718.3% | 1,522 | $1K |
| Islay Capital Management, LLC | 0.00% | No change | 169 | $160 |
| Grove Bank & Trust | 0.00% | New | 100 | $95 |
| BNP Paribas Financial Markets | 0.00% | Reduce -3.0% | 64 | $61 |
| Allworth Financial LP | 0.00% | No change | 13 | $13 |
"% of holder's portfolio" is FBLG's weight in each manager's 13F, not the share of Fibrobiologics Inc. the manager owns.